Related Experiment Video
Updated: Jul 2, 2025
07:34
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
667
Assessment of Ki-67 expression in cases of prostatic carcinoma and its correlation with clinical outcomes
1Department of Pathology, Regency Hospital, Kanpur, Uttar Pradesh, India.
Indian Journal of Pathology & Microbiology
|February 23, 2024
Summary
High Ki-67 expression in prostate cancer indicates a greater risk of distant metastasis and poorer survival rates. This marker can help assess prostate cancer lethality, guiding treatment decisions and reducing overtreatment.
Area of Science:
- Oncology
- Pathology
Background:
- Prostate cancer treatment decisions are complex due to variable tumor behavior.
- Improved markers are needed to identify lethal prostate cancer and prevent overtreatment of indolent cases.
Purpose of the Study:
- To assess Ki-67 expression in prostate carcinoma.
- To correlate Ki-67 expression with clinical outcomes.
Main Methods:
- Single-center retrospective descriptive study of 50 prostate adenocarcinoma cases.
- Inclusion of archival biopsy specimens with five-year follow-up.
- Recording of clinical outcomes including distant metastases, disease-specific survival, and overall survival.
Main Results:
- 78% of prostate carcinoma cases showed positive Ki-67 expression, with a mean staining index of 15.22%.
- High Ki-67 staining index was significantly associated with a higher rate of distant metastasis.
- Cases with high Ki-67 expression demonstrated poorer disease-specific and overall survival.
Conclusions:
- Ki-67 expression is a valuable prognostic marker in prostate cancer.
- Ki-67 can aid in assessing prostate cancer lethality.
- This marker can be used alongside established parameters to refine treatment strategies.
